Thanks Dr. T. The Pilar3 effectively being a combination of Pillar1 and Pillar 3 gives me confidence in the success of the trial.
Out of all the preclinical studies demonstrating Bisantrene as a potent FTO inhibitor, and the historical clinical results on AML, if the trial is designed rightly for the FTO, then we might see a better response in the FTO trial than the historical chemo trial, for the AML.
High chance of both being a success anyways, IMO..
- Forums
- ASX - By Stock
- RAC
- Ann: Quarterly Activity Report & Appendix 4C
Ann: Quarterly Activity Report & Appendix 4C, page-83
-
- There are more pages in this discussion • 45 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.88 |
Change
-0.060(3.09%) |
Mkt cap ! $313.4M |
Open | High | Low | Value | Volume |
$1.95 | $1.95 | $1.84 | $524.7K | 279.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1200 | $1.88 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.93 | 7978 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 351 | 1.870 |
1 | 1400 | 1.865 |
1 | 17396 | 1.860 |
1 | 900 | 1.855 |
2 | 960 | 1.850 |
Price($) | Vol. | No. |
---|---|---|
1.880 | 2275 | 1 |
1.905 | 234 | 1 |
1.935 | 7958 | 1 |
1.940 | 2577 | 1 |
1.945 | 5405 | 1 |
Last trade - 13.57pm 15/07/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online